News | February 28, 2010

Patients Prefer Iohexol Contrast Over Diatrozoate

February 28, 2010 - Patients expressed a statistically significant preference for the taste of iohexol over diatrozoate, a feature that is especially beneficial for very ill patients whom have trouble tolerating the taste of contrast agents, concluded a recent study.

Researchers from Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Missouri and the Milton S. Hershey Penn State Medical Center conducted a study comparing the tolerability of iodine-based oral contrast agents, Omnipaque (iohexol) and Gastroview (meglumine sodium diatrizoate). The purpose of the study was to compare the efficacy and patient acceptance of iohexol verus meglumine sodium diatrozoate for abdominal and pelvic CT scans.

Researchers presented on February 21 at the Abdominal Radiology Course Meeting held by the Society of Gastrointestinal Radiology and The Society of Uroradiology in Orlando.

The study also concluded that:

- There was no statistically significant difference between the two agents in the incidence of adverse reactions.

- The extent and density of GI tract opacification also were similar between the two groups.

- The cost of the two agents is comparable given the current low cost of low osmolar contrast agents.

For more information: www.mir.wustl.edu

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
Overlay Init